Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19Business Wire • 12/22/21
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality ConcernsBusiness Wire • 12/22/21
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research CollaborationBusiness Wire • 12/21/21
European Commission Expands Use Of Remdesivir In COVID-19 Patients Not On Supplemental OxygenBenzinga • 12/21/21
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease ProgressionBusiness Wire • 12/21/21
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowZacks Investment Research • 12/17/21
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in JapanBusiness Wire • 12/16/21
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma PatientsBenzinga • 12/14/21
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell LymphomaBusiness Wire • 12/13/21
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular LymphomaBusiness Wire • 12/11/21
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell LymphomaBusiness Wire • 12/11/21
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell LymphomaBusiness Wire • 12/11/21
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT StudyBusiness Wire • 12/10/21
